J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

ABC News medical contributor Dr. John Brownstein breaks down the latest ... shed more weight over a shorter period of time than Novo Nordisk’s Wegovy. The Biden administration has proposed ...

VANCOUVER, British Columbia and PERTH, Australia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- HIGHLIGHTS – FOURTH QUARTERThree new high ...

Novo Nordisk should enjoy years of growth as more ... If they do, it could carve out sizable positions in these massive markets. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary ...

Sanders has repeatedly called on Novo Nordisk to lower the price of its drugs ... With assistance from Madison Muller, John Lauerman and John Tozzi.

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

Doctors have begun noticing a trend: they all seem to get full before finishing dinner, and it's likely thanks to drugs like ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...